期刊文献+

左西孟旦治疗急性心肌梗死后心力衰竭的临床效果观察 被引量:14

Curative effect of levosimendan on the patients with acute myocardial infarction complicated with heart failure
原文传递
导出
摘要 目的:观察左西孟旦对急性心肌梗死后心力衰竭的临床治疗效果。方法:选择本院80例急性心肌梗死后心力衰竭患者,根据治疗途径的差异将其划分为对照组和观察组,前者接受心梗后心衰常规治疗,后者在常规治疗的同时选择左西孟旦进行联合治疗,两组患者均接受综合护理。结果:接受治疗后,观察组的平均BNP指标为352.7±11.2pg/m L,明显低于与对照组的473.8±12.2pg/m L;观察组有效率明显高于对照组。结论:针对急性心肌梗死后心力衰竭患者,选择左西孟旦进行治疗能够取得良好效果。 Objective To observe the effect of levosimendan on the patients with acute myocardial infarction(AMI) complicated with heart failure(HF). Methods All the 80 patients with AMI and HF are randomly divided into observation group(40cases)and control group(40 cases). The tobservation group was treated with levosimendan. The control group was treated with dobutamine. Results After the treatment, the average BNP index of the observation group was 352.7 + 11.2pg/m L. Significantly lower than that of the control group of 473.8 + 12.2pg/m L. The effective rate of the observation group was significantly higher than that of the control group. Conclusion The treatment can achieve good results on patient with AMI and HF.
作者 蒋科 余一知
机构地区 长沙市第一医院
出处 《湖南师范大学学报(医学版)》 2016年第3期114-115,116,共3页 Journal of Hunan Normal University(Medical Sciences)
关键词 左西孟旦 急性心肌梗死 心力衰竭 治疗 levosimendan acute myocardial infarction heart failure
  • 相关文献

参考文献7

二级参考文献54

  • 1Papp Z, Csapo K, Pollesello P, et al. Pharamacological mechanisms contributing to the clinical efficacy of levosimendan[ J]. Cardivoasc Drug Rev,2005,23 ( 1 ) :71 - 98.
  • 2Fotholeu H, Duman D. A promising new inotrope:levosimendan[ J]. Anadolu Kardiyol Derg,2010,10 (2) : 176 - 182.
  • 3郭攀,王平,孙漾丽,等.左西孟旦治疗急性心力衰竭62例疗效观察[J].中华全科医学,2013,11(5):680-681.
  • 4吴士礼,包宗明,史晓军,等.急性冠脉综合征患者应用左西孟旦治疗的意义[J].中国心血管病研究杂志,2011(5).
  • 5Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study):a randomized double-blind trial[J].Lancet,2002,360(9328):196-202.
  • 6Moiseyev VS,Pōder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer.Levosimendan,in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo-controlled,double-blind study(RUSSLAN)[J].Eur Heart J,2002,23(18):1422-1432.
  • 7Cleland JG,Ghosh J,Freemantle N,et al.Clinical trials update and cumulative meta-analyses from the American College of Cardiology:WATCH,SCD-HeFT,DINAMIT,CASINO,INSPIRE,STRATUS-US,RIO-Lipids and cardiac resynchronisation therapy in heart failure[J].Eur J Heart Fall,2004,6(4):501-508.
  • 8Lehtonen L.Levosimendan:a calcium-sensitizing agent for the treatment of patients with decompensated heart failure[J].Curr Heart Fail Rep,2004,1(3):136-144.
  • 9Ishitani T,Hattori Y,Sakuraya F,et al.Effects of Ca2+sensitizers on contraction,[Ca2+]i transient and myofilament Ca2+sensitivity in diabetic rat myocardium:potential usefulness as inotropic agents[J].J Pharmacol Exp Ther,2001,298(2):613-622.
  • 10Dec GW.Acute decompensated heart failure:the shrinking role of inotropic therapy[J].Am Coil Cordial,2005,46(1):65-67.

共引文献57

同被引文献109

引证文献14

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部